<?xml version='1.0' encoding='utf-8'?>
<document id="28932966"><sentence text="Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment."><entity charOffset="0-11" id="DDI-PubMed.28932966.s1.e0" text="Regorafenib" /></sentence><sentence text="We report our institutional observations of ten patients with advanced hepatocellular carcinoma (HCC) (seven and three were Child-Pugh class A and B, respectively) who received compassionate regorafenib therapy between June 2016 and January 2017" /><sentence text=" These patients did not fit the rigid criteria of a clinical trial and represented the use of regorafenib in an everyday clinic situation"><entity charOffset="94-105" id="DDI-PubMed.28932966.s3.e0" text="regorafenib" /></sentence><sentence text="" /><sentence text="Regorafenib (160 mg P"><entity charOffset="0-11" id="DDI-PubMed.28932966.s5.e0" text="Regorafenib" /></sentence><sentence text="O" /><sentence text=" daily) was administered to patients on a 4-week cycle (3 weeks on, 1 week off) until disease progression (assessed using mRECIST criteria) or discontinuation secondary to toxicity (assessed using CTCAE criteria)" /><sentence text=" Relevant clinical data were abstracted from patient medical records and reviewed retrospectively" /><sentence text="" /><sentence text="The median duration of patient treatment was 6" /><sentence text="6 weeks, and the median time to disease progression was 12" /><sentence text="5 weeks" /><sentence text=" Most common treatment emergent adverse events were fatigue, diarrhea, and hand-foot skin reaction" /><sentence text=" Elevated AST and ALT were the most commonly observed laboratory-assessed adverse events, which reached grade 3 status in the Child-Pugh class B patients only" /><sentence text=" We observed intolerance to regorafenib treatment in one patient who had previously received a liver transplant"><entity charOffset="28-39" id="DDI-PubMed.28932966.s15.e0" text="regorafenib" /></sentence><sentence text=" We also saw lithium toxicity in one patient receiving long-term lithium treatment, suggesting a potential and unexpected drug-drug interaction with regorafenib"><entity charOffset="13-20" id="DDI-PubMed.28932966.s16.e0" text="lithium" /><entity charOffset="65-72" id="DDI-PubMed.28932966.s16.e1" text="lithium" /><entity charOffset="149-160" id="DDI-PubMed.28932966.s16.e2" text="regorafenib" /><pair ddi="false" e1="DDI-PubMed.28932966.s16.e0" e2="DDI-PubMed.28932966.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28932966.s16.e0" e2="DDI-PubMed.28932966.s16.e1" /><pair ddi="false" e1="DDI-PubMed.28932966.s16.e0" e2="DDI-PubMed.28932966.s16.e2" /><pair ddi="false" e1="DDI-PubMed.28932966.s16.e1" e2="DDI-PubMed.28932966.s16.e1" /><pair ddi="false" e1="DDI-PubMed.28932966.s16.e1" e2="DDI-PubMed.28932966.s16.e2" /></sentence><sentence text="" /><sentence text="Taken together, our observations indicate that regorafenib is beneficial in the treatment of patients with advanced HCC who progressed on or demonstrated intolerance to sorafenib therapy; however, careful selection and close monitoring of patients is necessary to maximize the benefit while minimizing the toxicities of regorafenib treatment"><entity charOffset="47-58" id="DDI-PubMed.28932966.s18.e0" text="regorafenib" /><entity charOffset="169-178" id="DDI-PubMed.28932966.s18.e1" text="sorafenib" /><entity charOffset="320-331" id="DDI-PubMed.28932966.s18.e2" text="regorafenib" /><pair ddi="false" e1="DDI-PubMed.28932966.s18.e0" e2="DDI-PubMed.28932966.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28932966.s18.e0" e2="DDI-PubMed.28932966.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28932966.s18.e0" e2="DDI-PubMed.28932966.s18.e2" /><pair ddi="false" e1="DDI-PubMed.28932966.s18.e1" e2="DDI-PubMed.28932966.s18.e1" /><pair ddi="false" e1="DDI-PubMed.28932966.s18.e1" e2="DDI-PubMed.28932966.s18.e2" /></sentence><sentence text="" /></document>